Shifting blame: Buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America

Transcult Psychiatry. 2016 Aug;53(4):465-87. doi: 10.1177/1363461516660884. Epub 2016 Aug 3.

Abstract

Growing nonmedical prescription opioid analgesic use among suburban and rural Whites has changed the public's perception of the nature of opioid addiction, and of appropriate interventions. Opioid addiction has been recast as a biological disorder in which patients are victims of their neurotransmitters and opioid prescribers are irresponsible purveyors of dangerous substances requiring controls. This framing has led to a different set of policy responses than the "War on Drugs" that has focused on heroin trade in poor urban communities; in response to prescription opioid addiction, prescription drug monitoring programs and tamper-resistant opioid formulations have arisen as primary interventions in place of law enforcement. Through the analysis of preliminary findings from interviews with physicians who are certified to manage opioid addiction with the opioid pharmaceutical buprenorphine, we argue that an increase in prescriber monitoring has shifted the focus from addicted people to prescribers as a threat, paradoxically driving users to illicit markets and constricting their access to pharmaceutical treatment for opioid addiction. Prescriber monitoring is also altering clinical cultures of care, as general physicians respond to heightened surveillance and the psychosocial complexities of treating addiction with either rejection of opioid dependent patients, or with resourceful attempts to create support systems for their treatment where none exists.

Keywords: buprenorphine; opioid maintenance treatment; prescription monitoring programs.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Buprenorphine / therapeutic use*
  • Humans
  • Interviews as Topic
  • New York City
  • Opiate Substitution Treatment / methods
  • Opioid-Related Disorders / drug therapy*
  • Practice Patterns, Physicians'
  • Prescription Drug Monitoring Programs
  • Social Class

Substances

  • Buprenorphine